Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 46

1.

Population Pharmacokinetics of Alemtuzumab (Campath) in Pediatric Hematopoietic Cell Transplantation: Towards Individualized Dosing to Improve Outcome.

Admiraal R, Jol-van der Zijde CM, Furtado Silva JM, Knibbe CAJ, Lankester AC, Boelens JJ, Hale G, Etuk A, Wilson M, Adams S, Veys P, van Kesteren C, Bredius RGM.

Clin Pharmacokinet. 2019 May 27. doi: 10.1007/s40262-019-00782-0. [Epub ahead of print]

PMID:
31131436
2.

Differential Elimination of Anti-Thymocyte Globulin of Fresenius and Genzyme Impacts T-Cell Reconstitution After Hematopoietic Stem Cell Transplantation.

Oostenbrink LVE, Jol-van der Zijde CM, Kielsen K, Jansen-Hoogendijk AM, Ifversen M, Müller KG, Lankester AC, van Halteren AGS, Bredius RGM, Schilham MW, van Tol MJD.

Front Immunol. 2019 Mar 6;10:315. doi: 10.3389/fimmu.2019.00315. eCollection 2019.

3.

A prospective, placebo controlled study on the humoral immune response to and safety of tetanus revaccination in myasthenia gravis.

Strijbos E, Huijbers MG, van Es IE, Alleman I, van Ostaijen-Ten Dam MM, Bakker J, van Zwet EW, Jol-van der Zijde CM, van Tol MD, Verschuuren JJ.

Vaccine. 2017 Nov 1;35(46):6290-6296. doi: 10.1016/j.vaccine.2017.09.078. Epub 2017 Oct 6.

PMID:
28992975
4.

Expansion of cytotoxic CD56bright natural killer cells during T-cell deficiency after allogeneic hematopoietic stem cell transplantation.

Lugthart G, Goedhart M, van Leeuwen MM, Melsen JE, Jol-van der Zijde CM, Vervat C, van Ostaijen-Ten Dam MM, Jansen-Hoogendijk AM, van Tol MJD, Lankester AC, Schilham MW.

J Allergy Clin Immunol. 2017 Nov;140(5):1466-1469. doi: 10.1016/j.jaci.2017.06.039. Epub 2017 Aug 1. No abstract available.

PMID:
28778795
5.

Alemtuzumab Induction and Delayed Acute Rejection in Steroid-Free Simultaneous Pancreas-Kidney Transplant Recipients.

Bank JR, Heidt S, Moes DJ, Roelen DL, Mallat MJ, van der Boog PJ, Vergunst M, Jol-van der Zijde CM, Bredius RG, Braat AE, Ringers J, van Tol MJ, Claas FH, Reinders ME, de Fijter JW.

Transplant Direct. 2016 Dec 19;3(1):e124. doi: 10.1097/TXD.0000000000000634. eCollection 2017 Jan.

6.

Neuronal antibodies in pediatric epilepsy: Clinical features and long-term outcomes of a historical cohort not treated with immunotherapy.

Wright S, Geerts AT, Jol-van der Zijde CM, Jacobson L, Lang B, Waters P, van Tol MJ, Stroink H, Neuteboom RF, Brouwer OF, Vincent A.

Epilepsia. 2016 May;57(5):823-31. doi: 10.1111/epi.13356. Epub 2016 Mar 21.

7.

Association between anti-thymocyte globulin exposure and CD4+ immune reconstitution in paediatric haemopoietic cell transplantation: a multicentre, retrospective pharmacodynamic cohort analysis.

Admiraal R, van Kesteren C, Jol-van der Zijde CM, Lankester AC, Bierings MB, Egberts TC, van Tol MJ, Knibbe CA, Bredius RG, Boelens JJ.

Lancet Haematol. 2015 May;2(5):e194-203. doi: 10.1016/S2352-3026(15)00045-9. Epub 2015 Apr 21.

PMID:
26688094
8.

Reactivation of Human Herpes Virus-6 After Pediatric Stem Cell Transplantation: Risk Factors, Onset, Clinical Symptoms and Association With Severity of Acute Graft-Versus-Host Disease.

Verhoeven DH, Claas EC, Jol-van der Zijde CM, Thijssen JC, Lankester AC, Bredius RG, Putter H, Kroes AC, Egeler RM, Schilham MW, van Tol MJ.

Pediatr Infect Dis J. 2015 Oct;34(10):1118-27. doi: 10.1097/INF.0000000000000824.

PMID:
26132825
9.

Pharmacokinetics of rituximab in a pediatric patient with therapy-resistant nephrotic syndrome.

Counsilman CE, Jol-van der Zijde CM, Stevens J, Cransberg K, Bredius RG, Sukhai RN.

Pediatr Nephrol. 2015 Aug;30(8):1367-70. doi: 10.1007/s00467-015-3120-8. Epub 2015 Jun 9.

10.

Impact of serotherapy on immune reconstitution and survival outcomes after stem cell transplantations in children: thymoglobulin versus alemtuzumab.

Willemsen L, Jol-van der Zijde CM, Admiraal R, Putter H, Jansen-Hoogendijk AM, Ostaijen-Ten Dam MM, Wijnen JT, van Kesteren C, Waaijer JL, Lankester AC, Bredius RG, van Tol MJ.

Biol Blood Marrow Transplant. 2015 Mar;21(3):473-82. doi: 10.1016/j.bbmt.2014.11.674. Epub 2014 Dec 5.

11.

Population pharmacokinetic modeling of Thymoglobulin(®) in children receiving allogeneic-hematopoietic cell transplantation: towards improved survival through individualized dosing.

Admiraal R, van Kesteren C, Jol-van der Zijde CM, van Tol MJ, Bartelink IH, Bredius RG, Boelens JJ, Knibbe CA.

Clin Pharmacokinet. 2015 Apr;54(4):435-46. doi: 10.1007/s40262-014-0214-6.

PMID:
25466602
12.

The effect of cidofovir on adenovirus plasma DNA levels in stem cell transplantation recipients without T cell reconstitution.

Lugthart G, Oomen MA, Jol-van der Zijde CM, Ball LM, Bresters D, Kollen WJ, Smiers FJ, Vermont CL, Bredius RG, Schilham MW, van Tol MJ, Lankester AC.

Biol Blood Marrow Transplant. 2015 Feb;21(2):293-9. doi: 10.1016/j.bbmt.2014.10.012. Epub 2014 Oct 16.

13.

The diagnostic value of interleukin-8 for the detection of bacteremia in pediatric hematopoietic stem cell recipients with febrile neutropenia.

Miedema KG, Vermont CL, Ball LM, de Bont ES, Kamps WA, van Tol MJ, Jol-van der Zijde CM, Tissing WJ.

Transplantation. 2014 Oct 27;98(8):e80-1. doi: 10.1097/TP.0000000000000434. No abstract available.

PMID:
25318571
14.

Early cytomegalovirus reactivation leaves a specific and dynamic imprint on the reconstituting T cell compartment long-term after hematopoietic stem cell transplantation.

Lugthart G, van Ostaijen-Ten Dam MM, Jol-van der Zijde CM, van Holten TC, Kester MG, Heemskerk MH, Bredius RG, van Tol MJ, Lankester AC.

Biol Blood Marrow Transplant. 2014 May;20(5):655-61. doi: 10.1016/j.bbmt.2014.01.018. Epub 2014 Jan 23.

15.

Gastrointestinal acute graft-versus-host disease in children: histology for diagnosis, mesenchymal stromal cells for treatment, and biomarkers for prediction of response.

Calkoen FG, Jol-van der Zijde CM, Mearin ML, Schweizer JJ, Jansen-Hoogendijk AM, Roelofs H, van Halteren AG, Egeler RM, van Tol MJ, Ball LM.

Biol Blood Marrow Transplant. 2013 Nov;19(11):1590-9. doi: 10.1016/j.bbmt.2013.08.006. Epub 2013 Aug 28.

16.

Multiple infusions of mesenchymal stromal cells induce sustained remission in children with steroid-refractory, grade III-IV acute graft-versus-host disease.

Ball LM, Bernardo ME, Roelofs H, van Tol MJ, Contoli B, Zwaginga JJ, Avanzini MA, Conforti A, Bertaina A, Giorgiani G, Jol-van der Zijde CM, Zecca M, Le Blanc K, Frassoni F, Egeler RM, Fibbe WE, Lankester AC, Locatelli F.

Br J Haematol. 2013 Nov;163(4):501-9. doi: 10.1111/bjh.12545. Epub 2013 Aug 31.

PMID:
23992039
17.

Anticarbamylated protein (anti-CarP) antibodies are present in sera of juvenile idiopathic arthritis (JIA) patients.

Muller PC, Anink J, Shi J, Levarht EW, Reinards TH, Otten MH, van Tol MJ, Jol-van der Zijde CM, Brinkman DM, Allaart CF, Hoppenreijs EP, Koopman-Keemink Y, Kamphuis SS, Dolman K, van den Berg JM, van Rossum MA, van Suijlekom-Smit LW, Schilham MW, Huizinga TW, Toes RE, Ten Cate R, Trouw LA.

Ann Rheum Dis. 2013 Dec;72(12):2053-5. doi: 10.1136/annrheumdis-2013-203650. Epub 2013 Jul 19. No abstract available.

PMID:
23873877
18.

Antibodies to anti-thymocyte globulin in aplastic anemia patients have a negative impact on hematopoietic SCT.

Jol-van der Zijde CM, Bredius RG, Jansen-Hoogendijk AM, Smiers FJ, Lankester AC, van Tol MJ.

Bone Marrow Transplant. 2012 Sep;47(9):1256-8. doi: 10.1038/bmt.2011.259. Epub 2012 Jan 23. No abstract available.

PMID:
22266763
19.

CD27 deficiency is associated with combined immunodeficiency and persistent symptomatic EBV viremia.

van Montfrans JM, Hoepelman AI, Otto S, van Gijn M, van de Corput L, de Weger RA, Monaco-Shawver L, Banerjee PP, Sanders EA, Jol-van der Zijde CM, Betts MR, Orange JS, Bloem AC, Tesselaar K.

J Allergy Clin Immunol. 2012 Mar;129(3):787-793.e6. doi: 10.1016/j.jaci.2011.11.013. Epub 2011 Dec 24.

20.

IgG antibodies to ATG early after pediatric hematopoietic SCT increase the risk of acute GVHD.

Jol-van der Zijde CM, Bredius RG, Jansen-Hoogendijk AM, Raaijmakers S, Egeler RM, Lankester AC, van Tol MJ.

Bone Marrow Transplant. 2012 Mar;47(3):360-8. doi: 10.1038/bmt.2011.166. Epub 2011 Sep 5.

PMID:
21892212
21.

Reduced thymic expression of ErbB receptors without auto-antibodies against synaptic ErbB in myasthenia gravis.

Vrolix K, Niks EH, Le Panse R, van Ostaijen-Ten Dam MM, Muris AH, Jol-van der Zijde CM, van Tol MJ, Losen M, Molenaar PC, van Zoelen EJ, Berrih-Aknin S, De Baets MH, Verschuuren JJ, Martínez-Martínez P.

J Neuroimmunol. 2011 Mar;232(1-2):158-65. doi: 10.1016/j.jneuroim.2010.10.024. Epub 2010 Dec 18.

PMID:
21168922
22.

Anti-citrullinated protein antibodies have a low avidity compared with antibodies against recall antigens.

Suwannalai P, Scherer HU, van der Woude D, Ioan-Facsinay A, Jol-van der Zijde CM, van Tol MJ, Drijfhout JW, Huizinga TW, Toes RE, Trouw LA.

Ann Rheum Dis. 2011 Feb;70(2):373-9. doi: 10.1136/ard.2010.135509. Epub 2010 Nov 10.

PMID:
21068094
23.

Impaired avidity maturation after tetanus toxoid booster in children with Down syndrome.

Kusters MA, Jol-van der Zijde CM, van Tol MJ, Bolz WE, Bok LA, Visser M, de Vries E.

Pediatr Infect Dis J. 2011 Apr;30(4):357-9. doi: 10.1097/INF.0b013e3181ff85a8.

PMID:
21057373
24.

B-cell maturation and antibody responses in individuals carrying a mutated CD19 allele.

Artac H, Reisli I, Kara R, Pico-Knijnenburg I, Adin-Çinar S, Pekcan S, Jol-van der Zijde CM, van Tol MJ, Bakker-Jonges LE, van Dongen JJ, van der Burg M, van Zelm MC.

Genes Immun. 2010 Oct;11(7):523-30. doi: 10.1038/gene.2010.22. Epub 2010 May 6.

PMID:
20445561
25.

Appearance of peripheral blood plasma cells and memory B cells in a primary and secondary immune response in humans.

Blanchard-Rohner G, Pulickal AS, Jol-van der Zijde CM, Snape MD, Pollard AJ.

Blood. 2009 Dec 3;114(24):4998-5002. doi: 10.1182/blood-2009-03-211052. Epub 2009 Oct 20.

26.

Restoration of the antibody response upon rabies vaccination in HIV-infected patients treated with HAART.

Gelinck LB, Jol-van der Zijde CM, Jansen-Hoogendijk AM, Brinkman DM, van Dissel JT, van Tol MJ, Kroon FP.

AIDS. 2009 Nov 27;23(18):2451-8. doi: 10.1097/QAD.0b013e328331a43b.

PMID:
19741483
27.

Mannose-binding lectin levels and infections in children after allogeneic hematopoietic SCT.

Chaudhry SH, Chaudhry S, Jansen-Hoogendijk AM, Jol van der Zijde CM, van Tol MJ, Roos A, Bredius RG.

Bone Marrow Transplant. 2010 Feb;45(2):289-93. doi: 10.1038/bmt.2009.159. Epub 2009 Jul 13.

PMID:
19597428
28.

Cellular and humoral responses to tetanus vaccination in Gabonese children.

van Riet E, Retra K, Adegnika AA, Jol-van der Zijde CM, Uh HW, Lell B, Issifou S, Kremsner PG, Yazdanbakhsh M, van Tol MJ, Hartgers FC.

Vaccine. 2008 Jul 4;26(29-30):3690-5. doi: 10.1016/j.vaccine.2008.04.067. Epub 2008 May 15.

PMID:
18539369
29.

Clinical fluctuations in MuSK myasthenia gravis are related to antigen-specific IgG4 instead of IgG1.

Niks EH, van Leeuwen Y, Leite MI, Dekker FW, Wintzen AR, Wirtz PW, Vincent A, van Tol MJ, Jol-van der Zijde CM, Verschuuren JJ.

J Neuroimmunol. 2008 Mar;195(1-2):151-6. doi: 10.1016/j.jneuroim.2008.01.013. Epub 2008 Apr 1.

PMID:
18384886
30.

A transient neonatal myasthenic syndrome with anti-musk antibodies.

Niks EH, Verrips A, Semmekrot BA, Prick MJ, Vincent A, van Tol MJ, Jol-van der Zijde CM, Verschuuren JJ.

Neurology. 2008 Apr 1;70(14):1215-6. doi: 10.1212/01.wnl.0000307751.20968.f1. No abstract available.

PMID:
18378885
31.

Association of smoking with the constitution of the anti-cyclic citrullinated peptide response in the absence of HLA-DRB1 shared epitope alleles.

Verpoort KN, Papendrecht-van der Voort EA, van der Helm-van Mil AH, Jol-van der Zijde CM, van Tol MJ, Drijfhout JW, Breedveld FC, de Vries RR, Huizinga TW, Toes RE.

Arthritis Rheum. 2007 Sep;56(9):2913-8.

32.

Resetting the adaptive immune system after autologous stem cell transplantation: lessons from responses to vaccines.

Brinkman DM, Jol-van der Zijde CM, ten Dam MM, te Boekhorst PA, ten Cate R, Wulffraat NM, Hintzen RQ, Vossen JM, van Tol MJ.

J Clin Immunol. 2007 Nov;27(6):647-58. Epub 2007 Aug 10.

33.

Isotype distribution of anti-cyclic citrullinated peptide antibodies in undifferentiated arthritis and rheumatoid arthritis reflects an ongoing immune response.

Verpoort KN, Jol-van der Zijde CM, Papendrecht-van der Voort EA, Ioan-Facsinay A, Drijfhout JW, van Tol MJ, Breedveld FC, Huizinga TW, Toes RE.

Arthritis Rheum. 2006 Dec;54(12):3799-808.

34.

Adenovirus infection in paediatric stem cell transplant recipients: increased risk in young children with a delayed immune recovery.

van Tol MJ, Kroes AC, Schinkel J, Dinkelaar W, Claas EC, Jol-van der Zijde CM, Vossen JM.

Bone Marrow Transplant. 2005 Jul;36(1):39-50.

PMID:
15908981
35.

Vaccination with rabies to study the humoral and cellular immune response to a T-cell dependent neoantigen in man.

Brinkman DM, Jol-van der Zijde CM, ten Dam MM, Vossen JM, Osterhaus AD, Kroon FP, van Tol MJ.

J Clin Immunol. 2003 Nov;23(6):528-38.

PMID:
15031640
36.

Immunoglobulins in children with epilepsy: the Dutch Study of Epilepsy in Childhood.

Callenbach PM, Jol-Van Der Zijde CM, Geerts AT, Arts WF, Van Donselaar CA, Peters AC, Stroink H, Brouwer OF, Van Tol MJ; Dutch Study of Epilepsy in Childhood.

Clin Exp Immunol. 2003 Apr;132(1):144-51.

37.
38.

Quality and quantity of the humoral immune response in healthy elderly and young subjects after annually repeated influenza vaccination.

de Bruijn IA, Remarque EJ, Jol-van der Zijde CM, van Tol MJ, Westendorp RG, Knook DL.

J Infect Dis. 1999 Jan;179(1):31-6.

PMID:
9841819
39.

The origin of IgG production and homogeneous IgG components after allogeneic bone marrow transplantation.

van Tol MJ, Gerritsen EJ, de Lange GG, van Leeuwen AM, Jol-van der Zijde CM, Oudeman-Gruber NJ, de Vries E, Radl J, Vossen JM.

Blood. 1996 Jan 15;87(2):818-26.

40.

Clonal dysregulation of the antibody response to tetanus-toxoid after bone marrow transplantation.

Gerritsen EJ, Van Tol MJ, Van 't Veer MB, Wels JM, Khouw IM, Touw CR, Jol-Van Der Zijde CM, Hermans J, Rümke HC, Radl J, et al.

Blood. 1994 Dec 15;84(12):4374-82.

41.

Immunoglobulin levels and monoclonal gammopathies in children after bone marrow transplantation.

Gerritsen EJ, van Tol MJ, Lankester AC, van der Weijden-Ragas CP, Jol-van der Zijde CM, Oudeman-Gruber NJ, Radl J, Vossen JM.

Blood. 1993 Dec 1;82(11):3493-502.

42.

Transfer of specific immunity from donor to recipient of an allogeneic bone marrow graft: evidence for donor origin of the antibody producing cells.

Labadie J, van Tol MJ, Dijkstra NH, van der Kaaden M, Jol-van der Zijde CM, de Lange GG, Zwaan FE, Vossen JM.

Br J Haematol. 1992 Oct;82(2):437-44.

PMID:
1419826
43.

Immunoblotting techniques for the detection of low level homogeneous immunoglobulin components in serum.

Nooij FJ, Van der Sluijs-Gelling AJ, Jol-Van der Zijde CM, Van Tol MJ, Haas H, Radl J.

J Immunol Methods. 1990 Dec 5;134(2):273-81.

PMID:
2254671
44.

Dot-immunobinding assay as an accurate and versatile technique for the quantification of human IgG subclasses.

Jol-Van der Zijde CM, Labadie J, Vlug A, Radl J, Vossen JM, Van Tol MJ.

J Immunol Methods. 1988 Apr 6;108(1-2):195-203.

PMID:
3351308
45.

IgG subclass representation within homogeneous immunoglobulins in immunodeficiency diseases.

Radl J, Jol-van der Zijde CM, van Tol MJ, Vossen JM.

Monogr Allergy. 1988;23:78-82. No abstract available.

PMID:
3260339
46.

IgD idiopathic paraproteinemia in the aging C57BL/KaLwRij mouse.

Radl J, Van den Berg P, Jol-van der Zijde CM.

J Immunol. 1980 May;124(5):2513-5. No abstract available.

PMID:
7365265

Supplemental Content

Loading ...
Support Center